Shire's ulcerative colitis drug gains expanded indication in US
This article was originally published in Scrip
Executive Summary
Shire's oral delayed-release mesalamine product Lialda won US approval on 18 July as a maintenance-of-remission therapy for patients with ulcerative colitis, a type of chronic inflammatory disease that produces sores or ulcers along the inside lining of the colon and is characterized by bloody diarrhea and often painful cramping in the abdomen.